---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073100"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:45:11.114549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027

## Summary
- Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.
- Net loss $41.6M ($2.95 per share) vs $52.4M loss ($3.76 per share) in Q2 2024.
- Cash and investments $175.9M at June 30, 2025; excludes $107.5M net proceeds from July 2025 offering; runway into Q1 2027.
- FDA Fast Track granted for rezpegaldesleukin in severe-to-very severe alopecia areata (July 2025).
- REZOLVE-AD Phase 2b met primary and key secondary endpoints at week 16; 52-week data expected early 2026.

## SEC filing metadata
- accession: 0001213900-25-073100
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/0001213900-25-073100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/ea0252183-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073100
- JSON: https://secwatch.observer/filing/0001213900-25-073100.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.